Compare HURA & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HURA | ECBK |
|---|---|---|
| Founded | 2009 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Banks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 182.5M |
| IPO Year | 2010 | 2022 |
| Metric | HURA | ECBK |
|---|---|---|
| Price | $2.18 | $21.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 162.8K | 6.7K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.93 | ★ 95.83 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.95 |
| Revenue Growth | N/A | ★ 3.64 |
| 52 Week Low | $0.41 | $14.83 |
| 52 Week High | $3.43 | $21.53 |
| Indicator | HURA | ECBK |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 49.76 |
| Support Level | $2.04 | $20.12 |
| Resistance Level | $2.24 | $20.79 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 87.50 | 39.39 |
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.